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Abstract
Background: A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse;
however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute
(RMRI), Me´decins Sans Frontie`res (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B
(Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the
characteristics of immunocompetent patients who relapsed following this regimen.
Methods and Principal Findings: This is an observational retrospective cohort study of all VL patients treated by the MSF
program from July 2007 to August 2012. Intravenous Ambisome was administered to 8749 patients with VL in four doses of
5 mg/kg (for a total dose of 20 mg/kg) over 4–10 days, depending on the severity of disease. Out of 8588 patients not
known to be HIV-positive, 8537 (99.4%) were discharged as initial cures, 24 (0.3%) defaulted, and 27 (0.3%) died during or
immediately after treatment. In total, 1.4% (n = 119) of the initial cured patients re-attended the programme with
parasitologically confirmed VL relapse, with a median time to relapse of 10.1 months. Male sex, age,5 years and$45 years,
a decrease in spleen size at time of discharge of #0.5 cm/day, and a shorter duration of symptoms prior to seeking
treatment were significantly associated with relapse. Spleen size at admission, hemoglobin level, nutritional status, and
previous history of relapse were not associated with relapse.
Conclusions: This is the largest cohort of VL patients treated with Ambisome worldwide. The risk factors for relapse
included male sex, age ,5 and $45 years, a smaller decrease in splenomegaly at discharge, and a shorter duration of
symptoms prior to seeking treatment. The majority of relapses in this cohort occurred 6–12 months following treatment,
suggesting that a 1-year follow-up is appropriate in future studies.
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Introduction
Visceral leishmaniasis (VL) is a neglected tropical disease that
results in the loss of an estimated 1 million disability-adjusted life
years annually in South East Asia [1]; it is typically fatal if
untreated. VL predominantly affects the poorest strata of society
and those with limited access to care [2]. The incidence is
estimated to be between 146,700 and 282,800 cases per year [3].
Fifty percent of VL cases worldwide occur in India, and up to 90%
of these in the state of Bihar.
Although complete parasite clearance is rarely achieved, it is
thought that patients with competent immune systems who are
successfully treated develop an effective lifelong cellular immune
response that suppresses residual parasite growth [4]. High relapse
rates in HIV-positive patients have been previously described
[5,6]. However, in nearly all studies assessing treatment effective-
ness, a proportion of immunocompetent patients relapse following
treatment despite negative end-of-treatment test-of-cure results.
Typically, these relapses occur within 6 months of initial treatment
with later recurrence considered rare [7]. Very little is known
regarding the characteristics of immunocompetent patients with
VL who relapse [8,9], particularly in the Indian context.
The aim of this observational retrospective cohort study was to
identify risk factors for relapse in immunocompetent patients who
had been treated with 20 mg/kg Ambisome for their primary
episode of VL. With the permission of the State Health Society of
Bihar and the support of the specialist VL research institute the
Rajendra Memorial Research Institute (RMRI), Me´decins Sans
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Frontie`res (MSF) has been treating patients with VL in Vaishali
district since 2007, in coordination with the National Vector
Borne Disease Control Programme of India. Between July 2007
and August 2012, a total of 8749 patients diagnosed with VL were
treated with intravenous 20 mg/kg liposomal amphotericin B
(Ambisome; Gilead Pharmaceuticals, Foster City, CA, USA). This
regimen has been shown to have a 6-month cure rate of 98% in
the Indian context [10].
Ambisome is a brand name for Liposomal Amphotericin B.
There are a number of preparations of Liposomal amphotericin B
available on the market; however due to the lack of standard and
widely applicable regulations or guidance for liposomal technol-
ogy, it is important that this specific preparation be named. At
time of publication, none of the rival preparations have undergone
peer reviewed non-inferiority studies against Ambisome nor
received stringent regulatory approval for use in VL. It is for this
reason that MSF and the WHO currently only use Ambisome
rather than other preparations. However it is urgent that clear
regulatory guidelines for endemic countries be established by a
normative setting organisation like the WHO and other existing
formulations be formally evaluated [11].
Using the data routinely collected from the MSF program, we
determined the demographic and clinical characteristics of 119
immunocompetent patients who presented back to the program
with parasitologically confirmed VL relapse. We then identified
possible risk factors for relapse by comparing these patients to the
8418 patients who were discharged as cured and were not known
to have relapsed.
Methods
MSF developed an integrated program within the existing
healthcare facilities in Vaishali district, Bihar, that utilised the
district hospital for inpatient care and five rural primary health
centers for ambulatory treatment in the community. Patients
diagnosed with VL at the primary health center level who were
aged ,2 years or .55 years, pregnant or lactating, severely
malnourished, had a hemoglobin (Hb) level of ,5 g/dL, or had a
history of relapse or HIV infection were referred to the district
hospital for further assessment.
All patients with a history consistent with VL (fever for .2
weeks and splenomegaly) had their diagnosis confirmed using
rK39 rapid diagnostic tests (Diamed-IT LEISH; DiaMed AG,
Cressier, Switzerland). Patients presenting with a previous history
of treatment for VL or with continued suspicion of VL despite
negative diagnostic tests were admitted at the district level hospital
or referred to a higher center (RMRI) for parasitological
confirmation.
Upon diagnosis of VL, the basic demographics of the patients
were recorded: clinical history, Hb level, malaria rapid diagnostic
test result, and nutritional status. Also recorded was ‘caste’, a form
of social stratification used in India; the categories used in the
study were: scheduled caste/tribe, other backward class and
general category. Other backward class is a collective term used by
the government of India for castes that are educationally and
socially disadvantaged. Scheduled caste/tribe are terms used for
two groups of historically disadvantaged people recognized in the
Constitution of India. These three groups combined account for
approximately 60% of India’s population. The general category is
for those who do not fit into the other categories and are,
therefore, not considered disadvantaged.
Initially, HIV tests were offered at the hospital level to those
who were deemed high-risk (e.g. patients who presented with VL
relapse or those who had a history suggestive of higher risk, such as
being a migrant worker). This was changed in March 2011 when
all inpatients aged.14 years were offered HIV testing. All women
of childbearing age were given urinary pregnancy tests.
Patients were treated with four doses of 5 mg/kg Ambisome
over 4–10 days, depending on the clinical severity. Initially, all
patients with VL were treated on days 0, 1, 4, and 9. However,
due to the increasing number of patients and the limited capacity
of the hospital, the treatment duration was reduced to 4
consecutive days at the hospital level for all clinically stable
patients. Patients given ambulatory treatment at the primary
health centers and clinically severe patients admitted to the
hospital continued to receive the 7–10 day regimen.
An initial cure was defined as improvement of symptoms,
cessation of fever, and reduction of spleen size at time of discharge.
Considering the risks associated with splenic puncture, a test-of-
cure was performed only on patients with suspected treatment
failure, particularly as an earlier field study using this regimen in
the same setting showed a 6 month final cure rate of .98% [10].
Fortunately, no patients during the 5-year study period were
suspected of treatment failure.
All patients were provided with health education regarding VL
and the possibility of relapse, and were advised to return to the
MSF-supported district hospital if symptoms recurred. Patients
who returned to the program with suspected relapse were matched
with their original records, and parasitological confirmation was
sought. If splenomegaly was present, splenic aspiration was
performed. In cases without splenomegaly, or where splenic
aspiration was contraindicated (e.g. low platelet count), bone
marrow aspiration was performed. All patients with confirmed VL
relapses and an unknown HIV status were offered an HIV test. All
patients testing positive for HIV were excluded from the analysis
(Figure 1).
Patients with a parasitologically confirmed relapse after
treatment with the 20 mg/kg Ambisome regimen were then
treated with 25 mg/kg Ambisome in 5 successive doses at the
district hospital level.
All data were entered into a standard Microsoft Excel database;
double data-entry was not performed. Database cleaning was
Author Summary
Visceral leishmaniasis (VL), also known as Kala azar,
accounts for the second-highest burden of parasitic
disease worldwide. Fifty percent of VL cases worldwide
occur in India, and up to 90% of these in the state of Bihar.
Up to 10% of VL patients relapse within 6 months of
treatment, particularly if co-infected with HIV. Limited data
are available regarding relapse in patients with intact
immune systems. Between 2007–2012, with support of the
Rajendra Memorial Research Institute(RMRI), Me´decins
Sans Frontie`res (MSF) treated VL patients in Bihar with
20 mg/kg liposomal amphotericin B (Ambisome). Here we
identify risk factors for relapse in immunocompetent
patients by comparing the demographics and clinical
characteristics of 119 patients testing negative for HIV who
experienced parasitologically-confirmed VL relapse against
those of the remaining 8418 patients not known to have
relapsed. Male sex, age ,5 years and $45 years, shorter
duration of symptoms prior to seeking treatment, and a
smaller reduction in spleen size by time of discharge were
all risk factors for relapse. The majority of relapses occurred
6–12 months post-treatment with Ambisome. The con-
ventional period of follow-up is 6 months. Considering the
aim of elimination in the Indian subcontinent, this data
suggests that 1-year follow-up is necessary.
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Figure 1. Flowchart of the selection procedure for the patient record analysis.
doi:10.1371/journal.pntd.0002536.g001
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performed at regular intervals, including checks for inconsistencies
and verification by comparing with the source document, when
available. An epidemiologist ensured that the database was well-
maintained and made regular quality audits of data transfer.
World Health Organization (WHO) Anthro and Anthro Plus
software (Geneva, Switzerland) were used to calculate the weight-
for-height Z-score for children aged,5 years and the BMI-for-age
Z-score for children aged $5–19 years. A retrospective analysis of
all routinely collected program data was then conducted using
SPSS version 19 (IBM, Chicago, IL, USA).
The variables considered during the analysis included: age, sex,
Hb level, spleen size at admission, decrease in spleen size at the
time of discharge, nutritional status, time to presentation (duration
of symptoms prior to seeking treatment), location of treatment
(inpatient vs ambulatory), duration of treatment with Ambisome (4
vs. 7–10 days), season at time of treatment (November–February
vs March–June vs July–October), caste, and history of previous
relapse. Due to the differences in treatment durations, the decrease
in spleen size at time of discharge variable was standardised by
dividing the change in spleen size by the number of days that the
patient was admitted, yielding an average value of cm change-per-
day of admission (#0.5 vs. .0.5 cm/day).
Ethics statement
This analysis met the Me´decins Sans Frontie`res Institutional
Ethics Review Committee’s criteria for a study involving the
analysis of routinely collected program data. Although a new
treatment in the Indian setting, the programme utilised a
recognised treatment for VL and was run in coordination with
the State Health Society through a memorandum of understand-
ing, which is the usual procedure for NGOs operating in this
context. All electronic data were analysed anonymously.
Results
Over the 5-year period from July 2007 to December 2012, 8749
patients with VL were treated in the MSF program (Figure 1).
Demographic data for the cured cohort and patients who
experienced VL relapses are in Table 1. The overall program
mortality and default from treatment rates were very low (0.3%
each). Overall, disproportionately more male patients (56.6%)
than female patients were treated; only 52.9% of the population in
Bihar is male [12]. Most patients were from lower castes, and
nearly half were aged ,15 years. Most patients had no previous
history of VL, and the monthly distribution of admissions reflected
the known seasonality of VL in Bihar.
Patients who died during treatment, defaulted, or were HIV-
positive were excluded from the final analysis (Figure 1). A total of
119 patients presented with parasitologically confirmed VL relapse
following initial discharge. The median (interquartile range) time
to relapse from initial treatment was 10.1 (7.1–13.8) months. Of
the 119 patients who relapsed: 18 (15.1%) relapsed within 6
months of treatment; 63 (52.9%) within 6–12 months; and 38
(31.9%) .12 months after treatment. There was no significant
difference in the meantime to relapse between the sexes (log rank
Mantel-Cox p=0.776) (Figure 2).
Demographic risk factors
Male patients had higher odds of relapsing (unadjusted odds
ratio [uOR] 1.8; 95% CI 1.2–2.6) compared with female patients.
Patients aged ,5 years (uOR 3.6; 95% CI 1.8–7.2) and $45 years
(uOR 2.2; 95% CI 1.2–1.4) were more likely to relapse than
patients aged $15 to ,30 years. Factors not associated with
relapse in the univariate analysis (p.0.05) included: caste; living in
an area where MSF was conducting information, education, and
communication activities as well as supporting the primary health
center; a history of previous relapse; location of treatment
administration (treatment camp or primary health center/hospi-
tal); and season or year of treatment.
Clinical risk factors
According to the univariate analysis, patients reporting a shorter
duration of symptoms prior to seeking treatment had higher odds
of relapsing. Compared with the baseline group of patients who
received treatment #4 weeks after developing symptoms (also
known as time to presentation), the odds of relapse progressively
decreased as the duration of symptoms prior to seeking treatment
increased, from 0.6 (95% CI 0.4–0.97) for those presenting .4 to
#8 weeks after symptoms occurred to 0.4 (95% CI 0.2–0.8) for
those presenting .8 weeks after symptoms occurred. Additionally,
patients who exhibited a decrease in spleen size of #0.5 cm/day
by the time of discharge appeared to have higher odds of relapse
(1.7; 95% CI 1.1–2.5) compared with those who exhibited a
decrease in spleen size of .0.5 cm/day. No other clinical factors
were significantly associated with risk of relapse (Table 2). Notably,
nutritional status, spleen size and Hb level upon admission, and
duration of treatment were not predictive of relapse.
Multivariate regression model of risk factors for relapse
A multivariate logistic regression model was developed for those
variables that were shown to be significant by univariate analysis
(p,0.05) (Table 3). Variables that were justified a priori or were
associated with relapse in other studies [8,9] were also included in
the multivariate analysis. These additional variables, which
included nutritional status and spleen size and Hb levels upon
admission, were added step-wise to the model. However, the
variables associated with relapse as determined by the univariate
analysis remained significant in the multivariate analysis, and those
that were non-significant in the univariate analysis did not attain
significance in the multivariate analysis.
Discussion
Debate regarding the role of reinfection rather than relapse in
recurrence of VL is ongoing, however recent evidence supports the
general consensus that relapse is more likely to be the cause [13].
Future studies investigating recurrence of VL will be strengthened
by the assessment of different immunological parameters and pre-
and post-relapse parasite fingerprinting in order to definitively
answer this question.
Risk factors for relapse
This cohort represents the largest number of patients with VL
treated with Ambisome both worldwide and on the Indian
subcontinent to date. Although based only in one district, this
program has treated an estimated 5.8% of all reported VL cases in
India between 2008 and 2011 [14]. The present study is also the
only India-based study that specifically examines risk factors for
and characteristics of relapse in immunocompetent patients, and
describes the distribution of VL relapses .6 months after
treatment. It is, therefore, of particular interest considering the
move towards lower dose Ambisome as the first-line therapy for
VL on the Indian subcontinent [7].
A strength of this study is the robust database that has been
maintained throughout the program and has minimal missing
data. A limitation is that all patients were not followed up
prospectively to determine relapse status, and as such the
identification of relapses depended on patients returning to the
Risk Factors of Relapse in Visceral Leishmaniasis
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programme for assessment if their symptoms recurred. This may
result in an underestimation of the number of relapses to the
20 mg/kg regimen.
There are limited data available regarding VL relapses in
immunocompetent patients, and risk factors for relapse appear to
vary from country to country. A retrospective study of 300 VL
patients treated with meglutamine antimoniate in Georgia
between 2002 and 2004 identified 21 cases of relapse. Among
these cases, age ,1 year, time to treatment of .90 days, and Hb
levels of ,6 g/dL were associated with relapse [8]. However, it is
unclear whether these patients were tested for HIV. No association
between relapse and spleen size nor sex was observed.
A more recent study examined patient characteristics and drug
regimens associated with VL relapse in South Sudan between
1999 and 2007. The treatment records for 166 patients with VL
who presented with relapses were compared with the treatment
records for 7924 primary VL patients who did not re-attend with
relapse [9]. This study found that larger spleen size upon
admission and at the time of discharge were strongly associated
with relapse, as was treatment with a short-course combination
treatment (17 days sodium stibogluconate/paromomycin vs 30
days sodium stibogluconate). Age, sex, nutritional status, mobility,
and treatment complications were not significantly associated with
relapse. The main limitation was missing data, which resulted in
Table 1. Association between demographic factors and VL relapse.
Risk factor Cured cohort Relapse cohort
Unadjusted odds
ratio (95% CI) p
Sex (n = 8537) 8418 119
Male 4745 (56.4) 83 (69.7) 1.8 (1.2–2.6) 0.003
Female 3673 (43.6) 36 (30.3) - -
Castea (n = 8486) 8368 118
Scheduled caste 2453 (29.3) 32 (27.1) 1.4 (0.7–2.7) 0.32
Other backward class 4624 (55.3) 74 (62.7) 1.7 (0.9–3.2) 0.08
General Category 1291 (15.4) 12 (10.2) - -
Living in MSF-supported blocks (n = 8537) 8418 119
No 4297 (51.0) 56 (47.1) 0.9 (0.6–1.2) 0.39
Yes 4121 (49.0) 63 (52.9) - -
Previous relapse (n = 8537) 8418 119
Multiple 18 (0.2) 1 (0.8) 3.9 (0.1–25.4) 0.23c
Single 299 (3.6) 4 (3.4) 0.95 (0.3–2.5) 1.00c
No 8101 (96.2) 114 (95.8) - -
Age, years (n = 8537) 8418 119
,5 574 (6.8) 17 (14.3) 3.6 (1.8–7.1) ,0.001
5 to ,15 3229 (38.4) 43 (36.1) 1.6 (0.9–2.9) 0.10
15 to ,30 1935 (23.0) 16 (13.4) - -
30 to ,45 1490 (17.7) 21 (17.6) 1.7 (0.9–3.3) 0.11
$45 1190 (14.1) 22 (18.5) 2.2 (1.2–4.3) 0.013
Treatment location (n = 8537) 8418 119
Treatment camps (ambulatory) 162 (1.9) 0 NA -
Primary health center (ambulatory) 1372 (16.3) 13 (10.9) 0.6 (0.3–1.1) 0.10
Hospital (inpatient) 6884 (81.8) 106 (89.1) - -
Season of treatment (n = 8537) 8418 119
March–June 3566 (42.4) 53 (44.5) 1.0 (0.7–1.6) 0.84
July–October 2527 (30.0) 33 (27.7) 0.9 (0.6–1.5) 0.74
November–February 2325 (27.6) 33 (27.7) - -
Year of treatmenta,b (n = 7471) 7359 112
2011 1692 (23.0) 31 (27.7) 1.4 (0.8–2.2) 0.22
2010 1614 (21.9) 25 (22.3) 1.1 (0.7–1.9) 0.61
2009 1468 (19.9) 21 (18.8) 1.1 (0.6–1.8) 0.84
2007–2008 2585 (35.1) 35 (31.3) - -
aThe remaining data were missing or incorrectly coded in the database.
bThe data from years 2007 and 2008 were combined, as operations began mid-2007. Patients treated in 2012 were excluded, as there would be limited time for relapse
to present.
cFisher’s Exact test.
doi:10.1371/journal.pntd.0002536.t001
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the inclusion of only 26.7% (166/621) of the relapses in the
analysis. Additionally, HIV testing was not performed for the
relapse patients, although the authors considered this unlikely to
be a factor for relapse in this group, as the estimated prevalence of
co-infection was only 0.5%.
Our results suggest that age ,5 and $45, male sex, a decrease
in spleen size of #0.5 cm/day at discharge, and a short duration
of symptoms prior to seeking treatment are risk factors for VL
relapse in immunocompetent patients in India. Younger patients
may be particularly susceptible to relapse due to the lack of a
mature immune system [8]. The increased number of male
patients presenting with relapse may be explained by the
possibility of limited access to care for females. Indeed, in an
analysis of the overall field outcomes of the MSF program in
Bihar, the proportion of females admitted to the program
progressively decreased in older age groups [Submitted to PLOS
NTD].
We are unable to explain the strong inverse correlation that
the present study revealed between the duration of symptoms
prior to seeking treatment (time to presentation) and relapse.
Indeed, this correlation is contrary to a priori knowledge, which
would predict an association between a longer duration of illness
and a more severe clinical presentation, and therefore more
serious outcomes. However, other indicators of prolonged
illness, such as low Hb level, poor nutritional status and
increased splenomegaly at time of admission, were also not
associated with relapse. It is possible that, in the Indian context,
a rapid presentation to the healthcare provider could itself
be an independent indicator of more severe illness or poorer
immune status. This association needs to be correlated
with other programmes’ outcomes and warrants further
investigation.
Figure 2. Uncensored Kaplan–Meier graph showing time to
relapse stratified by sex (n=119). *Log rank (Mantel-Cox)
p=0.776.
doi:10.1371/journal.pntd.0002536.g002
Table 2. Association between clinical features and relapse of VL.
Risk factora Cured cohort Relapse cohort
Unadjusted odds
ratio (95% CI) p
Nutritional status (n = 7055) 6949 106
Severe acute malnutrition 1233 (17.7) 19 (17.9) 1.1 (0.6–1.8) 0.73
Moderate acute malnutrition 1587 (22.8) 29 (27.4) 1.3 (0.8–2.0) 0.25
Normal 4129 (59.4) 58 (54.7) - -
Duration of symptoms prior to seeking treatment, weeks (n = 8533) 8414 119
#4 4909 (58.3) 86 (72.3) - -
.4 to #8 2070 (24.6) 22 (18.5) 0.6 (0.4–0.97) 0.036
.8 1435 (17.1) 11 (9.2) 0.4 (0.2–0.8) 0.008
Spleen size at admission, cm (n = 8534) 8415 119
,3 1229 (14.6) 21 (17.6) - -
3–6 4306 (51.2) 63 (52.9) 0.9 (0.5–1.4) 0.54
.6 2880 (34.2) 35 (29.4) 0.7 (0.4–1.2) 0.22
Decrease in spleen size at discharge, cm/day (n = 8513) 8394 119
#0.5 4995 (59.5) 85 (71.4) 1.7 (1.1–2.5) 0.008
.0.5 3399 (40.5) 34 (28.6) - -
Hb level, g/dL (n = 8512) 8393 119
,6 1082 (12.9) 12 (10.1) 0.7 (0.3–1.3) 0.22
$6–#8 2782 (33.1) 43 (36.1) 0.9 (0.6–1.5) 0.72
.8–#10 2746 (32.7) 34 (28.6) 0.7 (0.4–1.2) 0.22
.10 1783 (21.2) 30 (25.2) - -
Duration of treatment, days (n = 8524) 8405 119
4 1709 (20.3) 21 (17.6) 0.8 (0.5–1.3) 0.47
7–10 6696 (79.7) 98 (82.4) - -
aWhere patient numbers are ,8537, the remaining data were missing or incorrectly coded in the database.
doi:10.1371/journal.pntd.0002536.t002
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Timing and characteristics of relapses
In India, the synthetic phospholipid derivative hexdecylpho-
sphocholine (miltefosine) is currently recommended by the Indian
National Programme as the first line treatment for VL. It is a 28-
day oral treatment but its use is limited by teratogenicity, which
restricts its use in pregnant and lactating women and requires 3–5
months of contraceptive cover for women of childbearing age [15].
Although miltefosine initially showed promising efficacy and
tolerability, recent studies in India [16,17] and Nepal [13] have
demonstrated relapse rates in immunocompetent patients of
between 6.8% to 10.8% at 6 months respectively, and up to
20.0% at 12 months in Nepal.
Over the past decade, several studies have examined liposomal
preparations of amphotericin B. For doses of Ambisome $10 mg/
kg, the efficacy at 6 months is .95% [11]. Following a pivotal
phase III study published in 2010 [18], the WHO expert
committee on leishmaniasis adopted a single 10 mg/kg dose
regimen as the recommended first-line treatment for VL in South
East Asia [7], a strategy that has yet to be introduced by the Indian
National Programme.
The results from the present study suggest that following
treatment with 20 mg/kg Ambisome, risk factors for VL relapse
include male sex, age ,5 years and $45 years, a slower decrease
in splenomegaly during treatment, and a shorter duration of
symptoms prior to seeking treatment. It also indicates that when
using this regimen the majority of relapses occur 6–12 months
post-treatment. Recent evidence from another study in Nepal
suggests that a significant number of patients relapse 6–12 months
post-treatment with miltefosine [13]. Given the move towards
treating VL patients with a single 10 mg/kg dose of Ambisome or
short-course combination therapies, and the aim of elimination in
the Indian subcontinent, we suggest that a 1-year follow-up is
essential and should be recommended for all VL treatments.
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